# Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma

> **NCT07233720** · — · RECRUITING · sponsor: **Henan Cancer Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT07233720
- **Lead sponsor:** Henan Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-18
- **Primary completion:** 2028-06
- **Final completion:** 2030-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07233720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07233720, "Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07233720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*